205 results on '"Vallianatou, Theodosia"'
Search Results
2. Contributors
3. Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia
4. Untargeted Metabolomics and Quantitative Analysis of Tryptophan Metabolites in Myalgic Encephalomyelitis Patients and Healthy Volunteers: A Comparative Study Using High-Resolution Mass Spectrometry.
5. Applying Spatial Metabolomics To Investigate Age- and Drug-Induced Neurochemical Changes.
6. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood–brain barrier
7. Identification of New Ketamine Metabolites and Their Detailed Distribution in the Mammalian Brain
8. Recent developments in the application of immobilized artificial membrane (IAM) chromatography to drug discovery
9. Inquiry-based Learning of Proteomics and Metabolomics
10. Identification of New Ketamine Metabolites and Their Detailed Distribution in the Mammalian Brain
11. Rapid Metabolic Profiling of 1 μL Crude Cerebrospinal Fluid by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Can Differentiate De Novo Parkinson’s Disease
12. Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition
13. Differential regulation of oxidative stress, microbiota-derived, and energy metabolites in the mouse brain during sleep
14. A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability
15. Comprehensive mapping of neurotransmitter networks by MALDI–MS imaging
16. The Impact of Physicochemical and Molecular Properties in Drug Design: Navigation in the 'Drug-Like' Chemical Space
17. Rapid Metabolic Profiling of 1 ÎŒL Crude Cerebrospinal Fluid by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Can Differentiate De Novo Parkinson's Disease
18. The potential of immobilized artificial membrane chromatography to predict human oral absorption
19. Rapid Metabolic Profiling of 1 μL Crude Cerebrospinal Fluid by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Can Differentiate De NovoParkinson’s Disease
20. In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review
21. Insight into the retention mechanism on immobilized artificial membrane chromatography using two stationary phases
22. Investigation of the retention behavior of structurally diverse drugs on alpha1 acid glycoprotein column: Insight on the molecular factors involved and correlation with protein binding data
23. Chapter 23 - Modeling ADMET properties based on biomimetic chromatographic data
24. Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation
25. Prediction Models for Brain Distribution of Drugs Based on Biomimetic Chromatographic Data
26. Prediction Models for Brain Distribution of Drugs Based on Biomimetic Chromatographic Data
27. Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems
28. Regional Brain Analysis of Modified Amino Acids and Dipeptides during the Sleep/Wake Cycle
29. Regional Brain Analysis of Modified Amino Acids and Dipeptides during the Sleep/Wake Cycle
30. Region-Specific and Age-Dependent Multitarget Effects of Acetylcholinesterase Inhibitor Tacrine on Comprehensive Neurotransmitter Systems
31. The Impact of Physicochemical and Molecular Properties in Drug Design: Navigation in the “Drug-Like” Chemical Space
32. TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition
33. Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain
34. sj-pdf-1-jcb-10.1177_0271678X211033358 - Supplemental material for Differential regulation of oxidative stress, microbiota-derived, and energy metabolites in the mouse brain during sleep
35. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia
36. Integration of Mass Spectrometry Imaging and Machine Learning Visualizes Region-Specific Age-Induced and Drug-Target Metabolic Perturbations in the Brain
37. TAAR1-Dependent and-Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition
38. Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy
39. Bromopyrylium Derivatization Facilitates Identification by Mass Spectrometry Imaging of Monoamine Neurotransmitters and Small Molecule Neuroactive Compounds
40. Cross-validated Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Quantitation Protocol for a Pharmaceutical Drug and Its Drug-Target Effects in the Brain Using Time-of-Flight and Fourier Transform Ion Cyclotron Resonance Analyzers
41. Cross-validated Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Quantitation Protocol for a Pharmaceutical Drug and Its Drug-Target Effects in the Brain Using Time-of-Flight and Fourier Transform Ion Cyclotron Resonance Analyzers
42. Bromopyrylium Derivatization Facilitates Identification by Mass Spectrometry Imaging of Monoamine Neurotransmitters and Small Molecule Neuroactive Compounds
43. Advanced Mass Spectrometry Imaging in Neuropharmacology
44. Simultaneous imaging of multiple neurotransmitters and neuroactive substances in the brain by desorption electrospray ionization mass spectrometry
45. Simultaneous imaging of multiple neurotransmitters and neuroactive substances in the brain by desorption electrospray ionization mass spectrometry
46. Advances in immobilized artificial membrane (IAM) chromatography for novel drug discovery
47. Mass Spectrometry Imaging in Drug Development
48. Mass Spectrometry Imaging in Drug Development
49. The Impact of Physicochemical and Molecular Properties in Drug Design: Navigation in the ˵Drug-Like″ Chemical Space.
50. Analysis of PPAR-α/γ Activity by Combining 2-D QSAR and Molecular Simulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.